SARS-CoV / SARS-CoV-2 spike antibody, chimeric MAb
Validated applications: ELISA , Neutralization
IHC, FCM, IF, IP et al. the applications have not been validated. (Antibody applications have not been validated with corresponding virus-positive samples. Optimal concentrations/dilutions must be determined by the end-user).
Peak of SARS coronavirus
- It is cross-reactive in ELISA with
SARS-CoV Peak S1 Protein (Cat # 40150-V08B1)
SARS-CoV-2 Spike S1 Protein (2019-nCoV) (Catalog # 40591-V08H)
SARS-CoV-2 (2019-nCoV) RBD protein spike (Cat # 40592-V08B)
- No cross-reactivity in ELISA with
MERS-CoV Spike S1 Protein (Cat # 40069-V08B1)
HCV-HKU1 (isolate N1) Spike S1 protein (Cat # 40021-V08H)
HCV-HKU1 (isolate N5) Spike S1 protein (Cat # 40602-V08H)
Spike S1 HCoV-NL63 Protein (Cat # 40600-V08H)
Spike S1 HCV-229E Protein (Cat # 40601-V08H)
HCV-OC43 Spike S1 + S2 ECD Protein (Cat # 40607-V08B)
Recombinant SARS-CoV Spike RBD Protein (Catalog # 40150-V08B2)
It is a chimeric monoclonal antibody that combines the constant domains of the human IgG1 molecule with mouse variable regions. The variable region was obtained from a mouse immunized with purified recombinant SARS-CoV peak RBD protein. The antibody was produced using recombinant antibody technology.
Mouse (variable region) / human (kappa constant / IgG1) monoclonal antibody Clone # D002
Purification: Protein A
Formulation: 0.2 μm filtered solution in PBS
This antibody is shipped as a liquid solution at room temperature. Upon receipt, please store immediately at the recommended temperature below.
This antibody can be stored at 2-8 ° C for one month without detectable loss of activity. Antibody products are stable for twelve months from the date of receipt when stored between -20 ℃ and -80 ℃. Without condoms. Avoid repeated freeze-thaw cycles.
Neutralization activity is measured by an in vitro microneutralization assay. The virus microneutralization (MN) test was performed on 293T-ACE2 cells infected with the SARS-CoV-2 Spike pseudovirus (2019-nCoV) under treatment with serial dilutions of neutralizing antibody. The infection was neutralized by increasing the concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog # 40150-D001). The inhibition rate was determined by comparing the relative light unit (RLU) of the luciferase reporter at different antibody concentrations. The IC50 is typically 46.762 µg / ml.